You are here: Industry Insights > tumor

News List

NICE publishes updated guidance with expanded recommendation for Oncotype DX pharmatimes
December 21, 2018
The National Institute for Health and Care Excellence (NICE) has announced the release of a second set of guidelines recommending three tests as options to help NHS clinicians decide whether
When good macrophages go bad worldpharmanews
December 03, 2018
Researchers at Children's Hospital Los Angeles reveal a mechanism by which some cancers trick healthy cells into protecting tumors.
Obesity both feeds tumors and helps immunotherapy kill cancer worldpharmanews
November 15, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors. The paradoxical findings, published today in Nature Medicine, give c
World Tumor Markers Testing Market 2018: Reagents & Instrumentation - Supplier Shares & Strategies, Country Segment Forecasts, Emerging Opportunities biospace
April 20, 2018
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.
Propranolol delays tumour growth and increases survival when combined with immunotherapy europeanpharmaceuticalreview
January 10, 2018
A common, inexpensive drug that is used to prevent heart attacks and lower blood pressure may also help melanoma patients live longer…
Higher mutational burdens in tumours linked to greater immunotherapy success, study finds pharmafile
December 22, 2017
New research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Cancer Institute for Cancer Immunotherapy has indicated that the mutational burden can provide a strong indicator as to whether a cancer will respond to checkpoint inhibito
FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic pro roche
December 05, 2017
Roche Corporation announced today that the FDA has approved the FoundationOne CDx ™ Foundation's comprehensive companion diagnostic method for personalized oncology treatment1
Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams worldpharmanews
October 10, 2017
Roche has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings.
Notable Labs nets $10M funding for personalized cancer treatment techNotable Labs nets $10M funding biospectrumasia
September 08, 2017
The company comes up with a report of the results, which an oncologist will use to guide treatment decisions for the patient
FDA approves first cancer treatment for any solid tumor with a specific biomarker europeanpharmaceuticalreview
May 25, 2017
The US Food and Drug Administration (FDA) granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).

Previous page 1 2 3 4 5 6 7 8 Next page